Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video that contained pointed criticism of the company’s recently approved gene therapy for Duchenne muscular ...

Sarepta posted Q1 2025 revenue of $744.86 million, beating the $683.36 million estimate. Full-year revenue guidance cut to $2.3 billion–$2.6 billion from prior $2.9 billion–$3.1 billion range ...

Sarepta Therapeutics Inc said the U.S. drug regulator could initially approve its gene therapy for a muscle wasting disorder for a smaller patient group after the agency deferred an accelerated ...

Sarepta Forward Looking Statement This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed ...